FDA Lifts Hold on Rocket’s Danon Disease Trial

Rocket Pharmaceuticals ( (RCKT) ) has provided an announcement.

On August 20, 2025, Rocket Pharmaceuticals announced that the FDA lifted the clinical hold on its Phase 2 trial of RP-A501 for Danon disease, allowing the trial to resume with a recalibrated dose. This decision underscores the FDA’s efficient review process and Rocket’s commitment to safety. The trial, which aims to evaluate the efficacy and safety of RP-A501, is crucial for addressing the high unmet medical need for Danon disease, a condition with limited treatment options.

The most recent analyst rating on (RCKT) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.

Spark’s Take on RCKT Stock

According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.

Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.

To see Spark’s full report on RCKT stock, click here.

More about Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing genetic therapies for rare disorders. The company employs a multi-platform approach to design gene therapies aimed at correcting the root causes of complex diseases, with a portfolio that includes treatments for Danon Disease, PKP2-arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy, among others.

Average Trading Volume: 4,794,420

Technical Sentiment Signal: Sell

Current Market Cap: $326.9M

Learn more about RCKT stock on TipRanks’ Stock Analysis page.